651 filings
Page 3 of 33
8-K
ra9n4a5nh6b4c
9 May 23
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
4:57pm
424B5
g0do41rapvlr
9 May 23
Prospectus supplement for primary offering
2:41pm
EFFECT
zxqoy9v2
8 May 23
Notice of effectiveness
12:15am
CORRESP
xh6fa2lswx srtpkp5r
3 May 23
Correspondence with SEC
12:00am
DEFA14A
wd09gr9 d19hy4
28 Apr 23
Additional proxy soliciting materials
4:21pm
8-K
6yr4 4xod3y
31 Mar 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:30am
UPLOAD
20dk1t
23 Mar 23
Letter from SEC
12:00am
8-K
rb5wshzhnxmbe8jol
15 Mar 23
Vaxart Provides Business Update and Full Year 2022 Financial Results
7:58pm
8-K
ky2ryz4r5v 53qv5
19 Dec 22
Vaxart Names Phillip Lee as Chief Financial Officer
5:25pm
8-K
99hdl418qgt1ll1uq
6 Dec 22
Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers
4:21pm
8-K
vv6a1
8 Nov 22
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
4:10pm
S-8
961ef1vn 283
21 Oct 22
Registration of securities for employees
9:04pm
8-K
vhh10vuv8uqval7hh
1 Sep 22
Regulation FD Disclosure
7:05am
8-K
t8vlte1a
25 Aug 22
Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors
4:09pm